Posted on

The most intense psychedelic?

ThField Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development

“​​I truly doubt that there is another psychedelic drug, anywhere, that can match [4-HO-DiPT] for speed, intensity, brevity, and sensitive to dose, at least one that is active orally.”

Field Trip Health’s (FTRP) first novel compound could produce the most intense experience of any oral psychedelic. 

It’s a more stable and soluble version of 4-HO-DiPT — a drug that induces an extremely powerful experience lasting 2-3 hours, according to Alexander Shulgin, the chemist who created it.

Considering he’s experimented with 55 different psychedelics, which he reviewed in “Tryptamines I Have Known and Loved,” we’ll take his word for it. 

Field Trip expects to receive a patent for the formulation next month. 

Field Trip Health Logo

PDF of article

Posted on

Psilocybin + CBD 🧠

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

The majority of patients with traumatic brain injury (TBI) also experience depression, and patients with severe TBI-related depression are 5x more likely to attempt suicide.

Wesana Health (WESA) is planning a study to see if the condition can be treated with one large dose of psilocybin in a clinic, followed by “self-administered maintenance doses” of psilocybin and CBD to sustain the benefits.

Researchers believe the treatment will promote neuroplasticity and neurogenesis while reducing neuroinflammation.

PDF of article

Posted on

Psychedelic therapy just got A LOT more accessible for Canadians

BREAKING: Canada Opens New Legal Pathways For Access To Psychedelics Treatment With Psilocybin And MDMA

Until now, the only way for patients to access psychedelic therapy outside a clinical trial was to apply for a Section 56 exemption and wait months on end to (possibly) receive approval from Health Canada.

Despite six more patients receiving the exemption over the holidays, the system remains flawed.

Thankfully, this Wednesday, Health Canada made an amendment to this thing called the Special Access Program (SAP), which enables healthcare practitioners to request access to drugs that are not yet approved, but have shown promise in clinical trials.

The amendment allows practitioners to request access to psilocybin and MDMA for their patients with serious, life-threatening, or treatment-adverse conditions. And the best part: requests are typically processed in just 1 day! 🎉

While this does not guarantee access for patients, it certainly feels like a big step in the right direction.

To learn more about the amendment, check out TheraPsil’s free webinar on Jan. 19th.

PDF of article

Benzinga
Posted on

Could this African shrub solve the opioid crisis?

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

MindMed (MNMD) developed a non-hallucinogenic molecule based on ibogaine, the psychoactive compound in the African iboga plant, and it’s showing potential to treat opioid addiction.

How? 🤔

The compound has demonstrated the ability to reduce opioid use and ease withdrawal symptoms by regulating excessive dopamine fluctuations.

An upcoming Phase 2a trial will put the compound to the test.

PDF of article

Posted on

Nature’s acid ✿

Morning Glory Has A Hell Of A Psychedelic Story

This common flower can make you trip?! 

The seeds of Morning Glory flowers contain a hallucinogenic compound that’s similar to LSD. It’s said to induce a dreamlike state and was even used in Mayan rituals to communicate with spirits.

(However, it can also cause nausea, vomiting, and cramping, so do with that information what you will 😉)

Research on the plant is gaining traction, so we may see it in clinical trials in the near future.

IFLScience logo

PDF of article

Posted on

MDMA works better than antidepressants

Latest Trials Confirm the Benefits of MDMA – the Drug in Ecstasy – for Treating PTSD

Plus, the effects are long-lasting!

A recent analysis found that, on average, patients who received MDMA-assisted therapy experienced a 22 point reduction in PTSD scores, whereas daily antidepressants only reduced scores by 6 to 14 points. 

One year after receiving the treatments, patients still reported benefits:

  • 84% reported improved feelings of well-being
  • 71% had fewer nightmares
  • 69% had less anxiety
  • 66% had improved sleep

Why is it so effective? MDMA reduces feelings of intense anxiety, allowing patients to open up and work through traumatic memories without fear.

PDF of article

Posted on

Is LSD the new Adderall?

MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD

MindMed (MNMD) is collaborating with universities in Switzerland and the Netherlands to study the effects of microdosing LSD on adults with ADHD. Patients will be assessed on symptoms of inattention, impulsivity, and hyperactivity after microdosing twice a week for six weeks. 

“The study builds on the growing evidence demonstrating LSD has the potential to improve mood and selective cognitive processes,” says the company’s new CEO, Robert Barrow, who was appointed this week.

PDF of article

Posted on

How psychedelics change your social life

How Do Psychedelics Change Your Personality? These Researchers Tried To Find Out

Researchers developed a personality model to test how psychedelics affect the qualities that help us build and maintain healthy relationships.

They discovered that after taking psychedelics, participants felt:

  • Less critical in their interactions with others,
  • Less anxious,
  • Less likely to get upset easily,
  • Greater feelings of social connectedness

How do you see psychedelics changing your relationships?

PDF of article

Posted on

Why psychedelics could be the key to world peace

Psychedelics: The newest tool in nuclear negotiations?

This scientist claims she helped end the Cold War with MDMA.

Carol Rosin—a space and missile defense consultant for the US—said she gave MDMA to Soviet scientists and military personnel prior to nuclear negotiations in 1985 (before the drug was illegal).

The plan was created with help from Rick Doblin, the founder of MAPS. 

“The thought was that if they can work through their fears and traumas and feel their connection to humanity, then that might be helpful,” Doblin explains.

While some are skeptical if this actually happened, MDMA releases oxytocin (aka the hormone of love and empathy), which could certainly help the opposing sides see eye to eye!  

logo footer

PDF of article

Posted on

You no longer have to be on your deathbed to eat mushrooms!

Exclusive: Three Canadians with mental health conditions receive legal access to psilocybin mushrooms

Up until this week, the only people in Canada that could legally access psilocybin therapy were patients with terminal illnesses. 

Things changed on Monday, when the non-profit organization TheraPsil helped three Canadians with mental health issues get Section 56 exemptions, granting them access to psilocybin therapy.

“This is a very clear indication that exemptions are now available for people who have anxiety, depression, addiction, and chronic pain,” says TheraPsil’s CEO. “It opens it up to everyone.”

PDF of article